Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 Commission File Number 000-51531 VIRACTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3295878 (State or other jurisdiction of incorporation) 2533 S. Coast Hwy. 101, Suite 210 Cardiff, California 92007 (Address of principal executive offices) ...

viracta VIRACTA CORPORATE OVERVIEW NASDAQ: VIRX I WWW.VIRACTA.COM Forward Looking Statements This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based on information currently available to management, including, without limitation, statements regarding: effects of the recent merger resulting in the combined company Viracta Therapeutics, Inc. ("Viracta" or the "C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year Ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51531 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class: Trading Symbol: Name of Each Exchange on Whic ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR For the transition period from to Commission file number: 000-51531 SUNESIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 94-3295878 (State or Ot ...

Financial Data and Key Metrics Changes - The company ended the quarter with $23.2 million in cash, cash equivalents, and restricted cash, bolstered by an additional $12.6 million raised from an equity offering [15] - Cash used in operating activities was $11.5 million for the six months ended June 30, 2020, compared to $13 million for the same period in 2019, primarily due to a net loss of $12.2 million and changes in operating assets and liabilities [16] Business Line Data and Key Metrics Changes - The company has committed resources towards the development of its first-in-class PDK-1 inhibitor, SNS-510, while evaluating the path forward for vecabrutinib [5][6] - Vecabrutinib continues to show an excellent safety profile but did not advance to Phase 2 due to insufficient clinical activity [10] Market Data and Key Metrics Changes - The company is focusing on SNS-510, which has shown synergistic activity when combined with other inhibitors in preclinical studies, particularly in breast cancer and lymphoma cell lines [8] Company Strategy and Development Direction - The company plans to review strategic alternatives to maximize shareholder value, which may include asset in-licensing, partnering, and mergers and acquisitions [14] - A workforce reduction of approximately 30% was implemented to right-size the company and preserve cash resources [13] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the industry-wide impact of COVID-19 and expressed pride in the team's commitment to maintain business continuity during this time [17] - The company is well-positioned to focus on the development of SNS-510 while maximizing the value of vecabrutinib [16] Other Important Information - The company expects to present additional preclinical findings for SNS-510 at a scientific meeting later in the year, with a target to file an IND by the first half of 2021 [9] Q&A Session Summary Question: Potential of SNS-510 across tumor types - Management indicated that SNS-510 could have broad activity against various cancers, particularly those with CDKN2A mutations, which may serve as useful biomarkers [20][23] Question: Strategic review impact on SNS-510 - Management confirmed that there are no specific gating items or expenses that would delay the progress of SNS-510 during the strategic review [34] Question: Mechanism of action of SNS-510 - Management clarified that SNS-510 enhances cytotoxicity in tumors with CDKN2A mutations by regulating the cell cycle, rather than directly acting on CDKN2A gene products [38][39]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51531 SUNESIS PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 94-3295878 (State or Other Ju ...

Sunesis Pharmaceuticals, Inc. (SNSS) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Par Hyare - Investor Relations Dayton Misfeldt - Interim Chief Executive Officer Judy Fox - Chief Scientific Officer, Executive Vice President, Research & Development Conference Call Participants Justin Kim - Oppenheimer Marc Frahm - Cowen Operator Ladies and gentlemen, thank you for standing by and welcome to Quarter First 2020 Sunesis Pharmaceutical Incorporated Earnings Conference Call. At th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51531 SUNESIS PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 94-3295878 (State or Other J ...

Sunesis Pharmaceuticals, Inc. (SNSS) Q4 2019 Results Earnings Conference Call March 10, 2020 4:30 PM ET Company Participants Willie Quinn - Chief Financial Officer, Senior Vice President, Finance and Corporate Development Dayton Misfeldt - Interim Chief Executive Officer Judy Fox - Chief Scientific Officer, Executive Vice President, Research & Development Conference Call Participants Hartaj Singh - Oppenheimer Jim Birchenough - Wells Fargo Marc Frahm - Cowen Operator Welcome to Sunesis Pharmaceuticals fourt ...

Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51531 SUNESIS PHARMACEUTICALS INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 94-3295878 (I.R.S. Empl ...